Compare APRE & AIRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | APRE | AIRE |
|---|---|---|
| Founded | 2006 | 2021 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.5M | 11.5M |
| IPO Year | 2019 | 2023 |
| Metric | APRE | AIRE |
|---|---|---|
| Price | $0.63 | $1.42 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 3 |
| Target Price | ★ $4.10 | $1.30 |
| AVG Volume (30 Days) | 57.0K | ★ 64.8K |
| Earning Date | 05-13-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 21.22 | ★ 60.34 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $4,518,498.00 |
| Revenue This Year | N/A | $129.06 |
| Revenue Next Year | N/A | $83.72 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 376.42 |
| 52 Week Low | $0.55 | $0.16 |
| 52 Week High | $1.93 | $3.98 |
| Indicator | APRE | AIRE |
|---|---|---|
| Relative Strength Index (RSI) | 40.85 | 38.95 |
| Support Level | $0.57 | $0.29 |
| Resistance Level | $0.83 | $2.17 |
| Average True Range (ATR) | 0.06 | 0.17 |
| MACD | -0.01 | -0.03 |
| Stochastic Oscillator | 34.44 | 17.45 |
Aprea Therapeutics Inc is a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers. It develops small molecule inhibitors designed to exploit genetic mutations in cancer to widen the therapeutic window and is intended to make treatments more effective at destroying cancer cells while sparing healthy tissue. The company's pipeline of clinical and preclinical programs includes APR-1051, a WEE1 inhibitor; ATRN-119 (Mosipasertib), an oral small molecule inhibitor of ataxia telangiectasia and Rad3-related, or ATR; and an early-stage program, APR-1602. These candidates are being developed for broad applications in cancer treatment.
ReAlpha Tech Corp is a real estate technology company. The group is engaged in an end-to-end commission-free homebuying platform. It develops and utilizes its artificial intelligence-focused technology stack to empower retail investor participation in short-term rental properties, which are real estate units listed for a rental term. It provides short-term rental investment opportunities to everyday investors. The company has developed technologies and tools that allow for the analysis of short-term rental properties using AI to provide insight into that property's potential profitability and ways to increase such profitability. The company's reportable segments are Homebuying Services and the Technology Services segment.